Negin Majedi brings a unique interdisciplinary perspective to Cornell’s Sibley School. A co-founder and former CEO of Symphony Biosciences, a biotech startup, Majedi’s research focuses on the mechanical properties of tissue and how these properties affect immune responses to cancer. Her work aims to create tumor-responsive biomaterials that can enhance the body’s immune system to fight solid tumors more effectively.
Majedi’s expertise in designing polymeric biomaterials and drug delivery platforms for cancer immunotherapy makes her an invaluable addition to Cornell’s research community. At Cornell, she is building a group dedicated to designing clinically translatable cancer therapies that mimic the mechanical environment of lymph nodes to boost immune function.
“I am excited to bring my experience in both the biotech and academic sectors to Cornell,” Majedi says. “By combining cutting-edge engineering with biological inspiration, we aim to develop new treatments for cancer that could save lives and transform healthcare.”